Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Type-1 cytokines regulate MMP-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo
Nesrine Boukhedouni, … , Julien Seneschal, Katia Boniface
Nesrine Boukhedouni, … , Julien Seneschal, Katia Boniface
Published May 5, 2020
Citation Information: JCI Insight. 2020;5(11):e133772. https://doi.org/10.1172/jci.insight.133772.
View: Text | PDF
Research Article Dermatology Inflammation

Type-1 cytokines regulate MMP-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo

  • Text
  • PDF
Abstract

Loss of melanocytes is the pathological hallmark of vitiligo, a chronic inflammatory skin depigmenting disorder induced by exaggerated immune response, including autoreactive CD8 T cells producing high levels of type 1 cytokines. However, the interplay between this inflammatory response and melanocyte disappearance remains to be fully characterized. Here, we demonstrate that vitiligo skin contains a significant proportion of suprabasal melanocytes, associated with disruption of E-cadherin expression, a major protein involved in melanocyte adhesion. This phenomenon is also observed in lesional psoriatic skin. Importantly, apoptotic melanocytes were mainly observed once cells were detached from the basal layer of the epidermis, suggesting that additional mechanism(s) could be involved in melanocyte loss. The type 1 cytokines IFN-γ and TNF-α induce melanocyte detachment through E-cadherin disruption and the release of its soluble form, partly due to MMP-9. The levels of MMP-9 are increased in the skin and sera of patients with vitiligo, and MMP-9 is produced by keratinocytes in response to IFN-γ and TNF-α. Inhibition of MMP-9 or the JAK/STAT signaling pathway prevents melanocyte detachment in vitro and in vivo. Therefore, stabilization of melanocytes in the basal layer of the epidermis by preventing E-cadherin disruption appears promising for the prevention of depigmentation occurring in vitiligo and during chronic skin inflammation.

Authors

Nesrine Boukhedouni, Christina Martins, Anne-Sophie Darrigade, Claire Drullion, Jérôme Rambert, Christine Barrault, Julien Garnier, Clément Jacquemin, Denis Thiolat, Fabienne Lucchese, Franck Morel, Khaled Ezzedine, Alain Taieb, François-Xavier Bernard, Julien Seneschal, Katia Boniface

×

Figure 1

Melanocyte loss results from defective adhesion of melanocytes and not from apoptosis.

Options: View larger image (or click on image) Download as PowerPoint
Melanocyte loss results from defective adhesion of melanocytes and not f...
(A) Representative immunofluorescence analysis showing melanocytes (red, Melan-A) and basal layer of epidermis stained with an anti–type VII collagen antibody (green) in control healthy skin, vitiligo perilesional skin, skin obtained from patients with concomitant vitiligo and psoriasis, and lesional psoriatic skin. Dashed lines represent dermoepidermal layer. Arrows show suprabasal melanocytes in different conditions. Scale bars: 50 μm (top), 20 μm (bottom). (B) Proportion of suprabasal melanocytes in control healthy skin (n = 5), stable or active vitiligo perilesional skin (n = 18; black squares: stable vitiligo, red squares: active vitiligo), perilesional skin of patients with association of vitiligo and psoriasis (n = 4), and lesional psoriatic skin (n = 4). (C) Representative analysis of epidermal cell death using cleaved caspase-3 antibody (green). Melanocytes were stained with anti-MITF antibody (red) in control healthy skin, stable and active vitiligo perilesional skin, or lesional skin from psoriasis, cutaneous lupus erythematous, and toxic epidermal necrolysis. Dashed lines represent dermoepidermal layer. Scale bar: 20 μm. (D) Proportion of cleaved caspase-3+ MITF+ basal (circles) or suprabasal (triangles) melanocytes in control healthy skin (n = 3), stable (n = 4) or active vitiligo perilesional skin (n = 6), lesional skin of psoriasis (n = 6), cutaneous lupus erythematous (n = 6), and toxic epidermal necrolysis (n = 3). (E) Representative immunofluorescence analysis of expression of E-cadherin (green) and melanocytes (red, Melan-A staining) in control healthy skin, perilesional stable or active vitiligo skin, and lesional psoriatic skin. Staining is representative of 10 independent patients. Dashed lines represent dermoepidermal layer. Arrows identify suprabasal melanocytes. Scale bars: 50 μm (right) and 10 μm (left). (F) Assessment by ELISA of soluble E-cadherin levels in the sera of healthy controls (n = 18) or patients with stable (n = 37), progressive (n = 38) vitiligo, or psoriasis (n = 20). Data show mean ± SEM. *P < 0.05, **P < 0.01; calculated with a Kruskal-Wallis test.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts